We have observed
17 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after January 30, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
METHODS OF TREATING DIABETES AND COMPOSITIONS CAPABLE OF SAME
PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING THE SAME
A NON-PROGRAMMER METHOD FOR CREATING SIMULATION-ENABLED 3D ROBOTIC MODELS FOR IMMEDIATE ROBOTIC SIMULATION, WITHOUT PROGRAMMING INTERVENTION
KEY GENES, MICRORNAS, OTHER NON-CODING RNAS AND COMBINATIONS THEREOF FOR IDENTIFYING AND REGULATING PLURIPOTENCY OF CELLS
Cargo handling system
METHOD OF ENGRAFTING CELLS FROM SOLID TISSUES
MIRNA AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH MELANOMA, OR IN DISEASES OR CONDITIONS ASSOCIATED WITH ACTIVATED BRAF PATHWAY
MALLEABLE HYDROGEL HYBRIDS MADE OF SELF-ASSEMBLED PEPTIDES AND BIOCOMPATIBLE POLYMERS AND USES THEREOF
Induction of exon skipping in eukaryotic cells
L-LACTATE PRODUCTION IN CYANOBACTERIA
CLONING AND EXPRESSION OF THE GENES ENCODING KEY CLOSTRIDIAL CATALYZING MECHANISMS FOR SYNGAS TO ETHANOL PRODUCTION AND FUNCTIONAL CHARACTERIZATION THEREOF
A NOVEL METHOD FOR DIAGNOSING Q-FEVER USING A CELLULAR IMMUNOLOGICAL TEST
Ship to shore crane with dual trolleys
ISOLATED HIGH AFFINITY ENTITIES WITH T-CELL RECEPTOR LIKE SPECIFICITY TOWARDS NATIVE COMPLEXES OF MHC CLASS II AND GLUTAMIC ACID DECARBOXYLASE (GAD) AUTOANTIGENIC PEPTIDES